X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (393) 393
life sciences & biomedicine (388) 388
anti-pd-1 (323) 323
immunotherapy (298) 298
oncology (254) 254
humans (226) 226
melanoma (169) 169
nivolumab (121) 121
pembrolizumab (110) 110
immunology (101) 101
cancer (99) 99
male (95) 95
female (94) 94
anti-ctla-4 (91) 91
programmed cell death 1 receptor - antagonists & inhibitors (91) 91
metastasis (86) 86
patients (83) 83
middle aged (78) 78
aged (77) 77
pd-1 protein (77) 77
tumors (77) 77
anti-pd-1 antibody (76) 76
cancer therapies (71) 71
apoptosis (68) 68
care and treatment (65) 65
anti-pd-l1 (61) 61
lung cancer (61) 61
immune checkpoint (60) 60
programmed cell death 1 receptor - immunology (59) 59
chemotherapy (57) 57
animals (55) 55
antibodies, monoclonal - therapeutic use (55) 55
ipilimumab (55) 55
melanoma - drug therapy (55) 55
neoplasms. tumors. oncology. including cancer and carcinogens (55) 55
analysis (53) 53
clinical trials (53) 53
lymphocytes (53) 53
cell death (52) 52
treatment outcome (52) 52
immune checkpoint inhibitors (51) 51
immunotherapy - methods (51) 51
adult (50) 50
antibodies (49) 49
antineoplastic agents - therapeutic use (42) 42
antineoplastic agents, immunological - therapeutic use (40) 40
metastases (40) 40
pd-l1 protein (40) 40
review (39) 39
aged, 80 and over (38) 38
antibodies, monoclonal, humanized - therapeutic use (38) 38
health aspects (37) 37
lymphocytes t (37) 37
b7-h1 antigen - antagonists & inhibitors (36) 36
medicine, research & experimental (36) 36
research & experimental medicine (36) 36
medicine & public health (35) 35
pd-l1 (35) 35
antibodies, monoclonal - adverse effects (34) 34
research (34) 34
t cells (34) 34
lung neoplasms - drug therapy (33) 33
medical prognosis (32) 32
antigens (30) 30
cytotoxicity (30) 30
immune-related adverse events (30) 30
lung cancer, non-small cell (30) 30
melanoma - pathology (30) 30
skin neoplasms - drug therapy (30) 30
antibodies, monoclonal, humanized - adverse effects (29) 29
antineoplastic agents - adverse effects (29) 29
biomarkers (29) 29
non-small cell lung cancer (29) 29
toxicity (29) 29
viral antibodies (29) 29
immune system (27) 27
mice (27) 27
ctla-4 antigen - antagonists & inhibitors (26) 26
drug therapy (26) 26
immune checkpoint inhibitor (26) 26
monoclonal antibodies (26) 26
usage (26) 26
anti-pd-1 therapy (25) 25
antineoplastic agents, immunological - adverse effects (25) 25
nivolumab - therapeutic use (25) 25
non-small cell lung carcinoma (25) 25
retrospective studies (25) 25
carcinoma, non-small-cell lung - drug therapy (24) 24
case report (24) 24
gene expression (24) 24
original research (24) 24
immunoglobulins (23) 23
neoplasm metastasis (23) 23
pharmacology & pharmacy (23) 23
b7-h1 antigen - immunology (22) 22
medical research (22) 22
neoplasms - immunology (22) 22
radiotherapy (22) 22
research article (22) 22
cell biology (21) 21
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (561) 561
French (15) 15
Japanese (7) 7
Korean (7) 7
German (5) 5
Russian (3) 3
Slovenian (2) 2
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical cancer research, ISSN 1557-3265, 04/2018, Volume 24, Issue 20, pp. 4960 - 4967
Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | anti–PD-1 | Immunotherapy | prognostic factors
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3354 - 3362
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 34, pp. 57826 - 57835
Purpose: To better understand the efficacy and safety of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) in patients with previously treated... 
Anti-PD-1/PD-L1 therapy | Pembrolizumab | NSCLC | Nivolumab | Atezolizumab | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology
Journal Article
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 02/2016, Volume 54, pp. 139 - 148
Journal Article
Oncoimmunology, ISSN 2162-402X, 09/2018, Volume 8, Issue 1, pp. e1515057 - e1515057
Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade... 
Head and neck squamous cell carcinoma | MEK inhibitor | anti-PD-1/PD-L1 mAb | immune recognition | immune infiltration | Oncology | Immunology | Life Sciences & Biomedicine | Science & Technology | anti-pd-1/pd-l1 mab | mek inhibitor | head and neck squamous cell carcinoma
Journal Article